|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Medtronic, Inc. (NYSE:MDT), a major manufacturer of cardio-vascular, orthopedic, spinal and other medical devices. |
|---|---|
| Transferring Party | Kyphon Inc. (NASDAQ:KYPH), a developer of diagnostic and minimally invasive technologies for the treatment of spinal conditions. |
| Sector | Medical Devices |
| Date | November 2, 2007 |
| Analysis Accelerates the growth of Medtronic's spinal business by offering minimally invasive spinal treatments that are simpler and less invasive than many traditional surgical treatments. Medtronic's spinal surgery focus has been on younger patients suffering from scoliosis and degenerative disc disease in the cervical and lumbar spine; Kyphon's focus has been on older patients suffering from vertebral compression fractures and spinal stenosis. While Medtronic primarily serves orthopedic and neurological surgeons who specialize in spinal surgery, Kyphon adds new call points: interventional radiologists and interventional neuroradiologists. Deal value - $3.9b, on revenue of $444.5m (8.8X) and EBITDA of $111.2 (35X). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |